Story

McKesson to Acquire Precision Medicine Group for $2.25 Billion, Shares Rise

ENTHMSVIIDZHZH-TWJAKOHI
Aug 25, 20261 min read
McKesson to Acquire Precision Medicine Group for $2.25 Billion, Shares Rise
Text size
Background

Shares of McKesson Corporation (NYSE:MCK) rose on Tuesday after the company announced a definitive agreement to acquire Precision Medicine Group for approximately $2.25 billion. The deal sent McKesson's stock up by 3.2%, reflecting investor optimism about the strategic expansion into clinical research and biopharmaceutical services.

Deal Details

Under the terms of the agreement, McKesson will acquire Precision Medicine Group (PMG), a global provider of services that support drug development and commercialization for biotechnology and pharmaceutical companies. The transaction is subject to customary closing conditions, including regulatory clearances, and a specific timeline for completion was not disclosed.

Once the acquisition is finalized, PMG will be integrated into McKesson’s Oncology & Multispecialty segment. PMG's offerings include biomarker intelligence, laboratory services, a global clinical research organization, and commercialization support.

Sample IUX Markets – In-articleAd

Strategic Rationale

McKesson stated the acquisition is a key step in advancing its strategy in the high-growth areas of oncology and multispecialty care. The addition of PMG is expected to enhance McKesson's capabilities in clinical trial execution and broaden its service offerings to biopharma partners.

"This acquisition represents another meaningful step in advancing our oncology and multispecialty strategy and reflects our continued commitment to providing patients with access to the highest quality of care," said Brian Tyler, chair and chief executive officer of McKesson, in the announcement. Margaret Keegan, CEO of PMG, added that joining McKesson will provide an opportunity to extend the company's expertise.

Read next

More on Stocks
Back to latest news

LATEST